Salubris (Suzhou) Pharmaceutical Co., Ltd. announced a private placement of CNY 26 million on January 18, 2023. The transaction will include participation from returning investor, Shenzhen Salubris Pharmaceuticals Co., Ltd. The company's registered capital will increase from CNY 212,430,446.29 to CNY 238,430,446.29. The transaction has been approved by the 35th meeting of the fifth board of directors of the company.